Abstract: The invention relates to the use of non-peptide bradykinin antagonists for the production of pharmaceuticals for the prevention and treatment of Alzheimer's disease. Suitable Compounds are non-peptide bradykinin antagonists which inhibit the actions of the Alzheimer's protein amyloid (.beta./A4) in isolated endothelial cells, such as for example, fused heterobicyclic fluoroalkyl derivatives.

Abstract: Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, process or their preparation, and their useHeterocyclic fluoroalkyl derivatives and fluoroalkoxy derivatives of the formula (I) having bradykinin-antagonistic action ##STR1## in which X.sub.1 -X.sub.3 are N or CR.sup.5, R.sup.1 and R.sup.2 are H or halogen, R.sup.3 and R.sup.4 are H, halogen, alkyl or alkenyl, R.sup.5 is H, halogen, (substituted) alkyl, O--R.sup.6, S--R.sup.6, NHR.sup.6, (substituted) aryl, (substituted)aryl-alkyl, --C(O)--OR.sup.6 or --C(O)--H, R.sup.6 and R.sup.8 H, alkyl, alkenyl or aryl-alkyl, R.sup.7 is (substituted) alkyl or (substituted) alkoxy, B is an aminocarboxylic acid, D is alkenediyl, alkanediyl or --(CH.sub.2).sub.n --Y.sub.p --(CH.sub.2).sub.m --, E is oxygen or sulfur, Y is oxygen, sulfur or NR.sup.8, n and m are a number 0-3, o is a number 1-3 and p is 0 or 1, and their physiologically tolerable salts and a process for their preparation are described.

Abstract: Sulfur-containing heterocyclic bradykinin antagonists, process for their preparation, and their useCompounds of the formula (I) ##STR1## in which one of the radicals X.sub.1, X.sub.2 or X.sub.3 is C--O--R.sup.2 and the other X.sub.1, X.sub.2, and X.sub.3, in each case, and X.sub.4, are then, identically or differently, N or CR.sup.1 ; R.sup.1 and R.sup.3 are, identically or differently, H, halogen, (C.sub.1 -C.sub.6)-alkyl, O--R.sup.6, S--R.sup.6, NHR.sup.6, (C.sub.6 -C.sub.12)-aryl, (C.sub.6 -C.sub.12)-aryl-(C.sub.1 -C.sub.3)-alkyl, C(O)--OR.sup.6, C(O)--H, (C.sub.2 -C.sub.5)-alkenyl, NO.sub.2, SO.sub.3 R.sup.7, CN or C(O)--NHR.sup.8, where alkyl, aryl and alkenyl can optionally be substituted.

Abstract: The invention relates to the use of nonpeptide bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders (hepatic cirrhosis and hepatic fibrosis), acute liver disorders and for the prevention of complications, in particular for the prophylaxis or treatment of portal hypertension, decompensation symptoms such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Abstract: A compound of the formula ##STR1## in which the symbols have the following meaning: X is a monocyclic radical having 3, 4 or 5 ring atoms,R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.12 and R.sup.13 are, for example, an alkyl radical,q is zero or 1,L is, for example, a methylene group andA is the radical, for example, of a heterocycleare highly active as antagonists of angiotensin II receptors.They can be used as pharmaceuticals or diagnostics.

Abstract: Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease.Antagonists for angiotensin II receptors of the AT.sub.1 subtype can be employed for the prophylaxis and combating of coronary heart disease.Furthermore these compounds, such as, for example, azoles of the formula (I) ##STR1## can also be used for the therapy of cognitive and erectile dysfunction.

Abstract: Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their useCompounds of the formula (I) ##STR1## in which R.sup.1 is, for example, ethyl,R.sup.2 is, for example, methyl,n is, for example, zero,R.sup.3 is, for example, COOH, andR.sup.4 is, for example, SO.sub.2 NHCONHCH.sub.3are highly active antagonists of angiotensin II receptors.

Abstract: A novel process for the preparation of a compound of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined in the text.

Abstract: Antagonists for angiotensin II receptors of the AT.sub.1 subtype can be employed for the prophylaxis and combating of coronary heart disease.Furthermore these compounds, such as, for example, azoles of the formula (I) ##STR1## can also be used for the therapy of cognitive and erectile dysfunction.

Abstract: Angiotensin II receptor antagonists for the treatment of disturbances in cardiac rhythm.Antagonists for angiotensin II receptors of the AT, subtype can be employed for combating cardiac arrhythmias, using azole derivatives.

Abstract: Imidazo-fused iso- and heterocycles, process for their preparation, compositions containing them and their useA compound of the formula ##STR1## in which the symbols have the following meaning: X is a monocyclic radical having 3,4 or 5 ring atoms,R.sup.1,R.sup.2,R.sup.3,R.sup.4,R.sup.12 and R.sup.13 are, for example, an alkyl radical,q is zero or 1,L is, for example, a methylene group andA is the radical, for example, of a heterocycleare highly active as antagonists of angiotensin II receptors. They can be used as pharmaceuticals or diagnostics.

Abstract: Amino acid derivatives with renin-inhibiting properties, a process for the preparation thereof, agents containing these, and the use thereofThe invention relates to renin-inhibiting amino acid derivatives of the formula ##STR1## in which R.sup.1 is a radical of a substituted nitrogen-containing heterocycle such as piperidine, X is CO, CS, SO.sub.2 or SO, Y is CH.sub.2, O or S, B is the radical of an amino acid of the formula H--B--OH, and R.sup.3, R.sup.4 and R.sup.5 are as defined in the description, a process for the preparation thereof, agents containing these, and the use thereof.

Abstract: The invention relates to a method for the treatment of cardiac and of vascular hypertrophy and/or hyperplasia by administration of angiotensin II receptor blockers, preferably of the imidazole, pyrrole, pyrazole, triazole or tetrazole type.